mitoxantrone has been researched along with Minimal Disease, Residual in 37 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "No cases of progression occurred in minimal residual disease (MRD) negative patients after six years of follow-up." | 2.94 | The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival. ( Bishton, MJ; Clifton-Hadley, L; Haynes, A; Lush, R; McMillan, A; Patmore, R; Rule, S; Turner, D; Wilson, W, 2020) |
| "Outcomes for children with acute myeloid leukemia (AML) have improved over the past 20 years even though the medications used for induction therapy have not changed." | 2.84 | Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials. ( Alexander, TB; Inaba, H; Pounds, S; Pui, CH; Ribeiro, RC; Rubnitz, JE; Triplett, BM; Wang, L, 2017) |
| "Maintenance treatment also reduced minimal residual disease (detected by WT1 and CBFβ-MYH11) in five of eight evaluable patients." | 2.79 | Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents. ( Audisio, E; Boccadoro, M; Bruno, B; Crisà, E; Ferrero, D; Festuccia, M; Frairia, C; Gatti, T; Giai, V; Marmont, F; Passera, R; Riera, L, 2014) |
| "In addition, minimal residual disease (MRD) in the marrow was studied 2 months after therapy, with MRD negativity defined as <0·01% CLL cells." | 2.76 | A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. ( Booth, GA; Brown, J; Cocks, K; Cohen, DR; Dearden, C; Ezekwisili, R; Fegan, C; Hillmen, P; Kennedy, DB; Mercieca, J; Milligan, DW; Pettitt, A; Pocock, C; Radford, J; Rawstron, AC; Sayala, HA; Smith, AF; Varghese, AM, 2011) |
| " During 2004 and 2005, 45 patients with newly diagnosed Ph+ ALL were treated in the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAAPH) 2003 study, in which imatinib was started with HAM (mitoxantrone with intermediate-dose cytarabine) consolidation in good early responders (corticosensitive and chemosensitive ALL) or earlier during the induction course in combination with dexamethasone and vincristine in poor early responders (corticoresistant and/or chemoresistant ALL)." | 2.73 | Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. ( Buzyn, A; Cayuela, JM; Chalandon, Y; de Labarthe, A; Delabesse, E; Dombret, H; Escoffre, M; Huguet-Rigal, F; Ifrah, N; Lhéritier, V; MacIntyre, E; Maury, S; Pigneux, A; Réa, D; Reman, O; Rousselot, P; Thomas, X; Vekemans, MC; Vernant, JP; Witz, F, 2007) |
| "To determine prognosis of acute promyelocytic leukemia (APL) failing to front-line therapy with all-trans retinoic acid (ATRA) and anthracyclines, outcome of 52 patients (32 M/20 F; age: 37, 3-72) included in PETHEMA trials LPA96 and LPA99 who presented with either molecular failure (MOLrel, n=16) or hematological relapse (HEMrel, n=36) was analyzed." | 2.73 | Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. ( Alvarez, C; Bolufer, P; Brunet, S; Colomer, D; Díaz-Mediavilla, J; Escoda, L; Esteve, J; González San Miguel, JD; González, M; Martín, G; Rivas, C; Rubio, V; Sánchez Godoy, P; Sanz, MA; Sayas, MJ; Tomás, JF; Tormo, M, 2007) |
| "The clinical significance of eradicating minimal residual disease (MRD) was also analyzed." | 2.73 | Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. ( Abella, E; Altés, A; Asensi, A; Aymerich, M; Bertazzoni, P; Bosch, F; Briones, J; Escoda, L; Ferrer, A; Font, L; Gardella, S; Giné, E; González, M; González-Barca, E; Montserrat, E; Muntañola, A; Pérez-Ceballos, E; Rozman, M; Sayas, MJ; Villamor, N, 2008) |
| "In this prospective randomized trial, we compared the efficacy and toxicity of cladribine (2-CdA) alone to 2-CdA combined with cyclophosphamide (CC) or cyclophosphamide and mitoxantrone (CMC) in untreated progressive chronic lymphocytic leukemia (CLL)." | 2.72 | Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG C ( Blonski, JZ; Calbecka, M; Ceglarek, B; Dmoszynska, A; Dwilewicz-Trojaczek, J; Gora-Tybor, J; Jamroziak, K; Kasznicki, M; Kloczko, J; Konopka, L; Kowal, M; Kuliczkowski, K; Robak, T; Skotnicki, AB; Stella-Holowiecka, B; Sulek, K; Tomaszewska, A; Warzocha, K; Zawilska, K, 2006) |
| "Seventy adults with acute promyelocytic leukemia were studied to clarify the significance of the level and kinetics of minimal residual disease (MRD) over their entire treatment course by realtime quantitative polymerase chain reaction." | 2.72 | The significance of minimal residual disease kinetics in adults with newly diagnosed PML-RARalpha-positive acute promyelocytic leukemia: results of a prospective trial. ( Cho, SG; Eom, KS; Kim, CC; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS, 2006) |
| "In this series confined to patients with minimal residual disease after initial therapy subjected to second-line intraperitoneal treatment, it appears to identify a poor prognostic (positive) subset for survival." | 2.70 | Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: a Southwest Oncology Group ancillary study. ( Alberts, DS; Belt, RJ; Cote, R; Felix, J; Hawes, D; Liu, PY; Muggia, FM; Terada, K; Wilczynski, S, 2002) |
| "Treatment results in childhood ALL continue to improve, and the expected current cure rates approach 75 to 80% of all children with ALL, including T-ALL and mature B-cell ALL, the two variants that, not too long ago, had a considerably poorer prognosis compared with the common form of BpALL." | 2.42 | Recent advances in pediatric acute lymphoblastic and myeloid leukemia. ( Ravindranath, Y, 2003) |
| "acute lymphoblastic leukemia-type chemotherapy that incorporated high-dose cytarabine was effective in achieving an minimal residual disease-negativity rate of 69% in evaluated patients, which was also predictive of better outcome." | 1.56 | Clinicoepidemiologic Profile and Outcome Predicted by Minimal Residual Disease in Children With Mixed-phenotype Acute Leukemia Treated on a Modified MCP-841 Protocol at a Tertiary Cancer Institute in India. ( Banavali, S; Gujral, S; Myint, HH; Narula, G; Patkar, N; Prasad, M; Subramanian, P; Tandon, S; Tembhare, P, 2020) |
| "Mortality of acute myeloid leukemia is still 60-70% in young (<60 years) adults and 90% in elderly (≥60 years) patients." | 1.40 | [Treatment of acute myeloid leukemia -- a single center experience (2007-2013)]. ( Batár, P; Bedekovics, J; Hevessy, Z; Illés, A; Kiss, A; Márton, A; Pinczés, L; Rejtő, L; Reményi, G; Selmeczi, A; Szász, R; Telek, B; Udvardy, M; Ujfalusi, A; Ujj, Z, 2014) |
| "Molecular relapse was detected in two patients by RQ-PCR four and six weeks, respectively before hematologic relapse occurred." | 1.33 | The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia. ( Döhner, H; Döhner, K; Eiwen, K; Fröhling, S; Schlenk, RF; Scholl, C, 2005) |
| "Minimal residual disease was monitored by qualitative and real-time quantitative PCR." | 1.33 | Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. ( Astolfi, M; Boccadoro, M; Bodoni, CL; De Marco, F; Drandi, D; Gianni, AM; Guidetti, A; Ladetto, M; Magni, M; Mantoan, B; Matteucci, P; Pagliano, G; Ricca, I; Tarella, C; Zanni, M, 2006) |
| "After each course, minimal residual disease was tested by specific reverse transcriptase-polymerase chain reaction (RT-PCR) (median sensitivity, 10(-5))." | 1.31 | Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial. ( Bilhou-Nabera, C; Blaise, D; Boiron, JM; Boucheix, C; Bourhis, JH; Buzyn, A; Cayuela, JM; Charrin, C; Delannoy, A; Dombret, H; Espérou, H; Fegueux, N; Fenaux, P; Fière, D; Gabert, J; Lhéritier, V; MacIntyre, E; Rigal-Huguet, F; Thomas, X; Vernant, JP, 2002) |
| "However, minimal residual disease (MRD) detected with DEK/CAN chimeric m-RNA by reverse transcription polymerase chain reaction (RT-PCR) was continuously observed, although decreased quantitatively, following several courses of consolidation and intensification chemotherapies." | 1.30 | [The detection of minimal residual disease by DEK/CAN chimeric m-RNA in a case of AML M2 with translocation t(6;9) (p23;q34) after chemotherapy and peripheral blood stem cell transplantation]. ( Ando, T; Ariyoshi, K; Hikiji, K; Kobayashi, M; Shinohara, K; Toyosawa, M, 1997) |
| "Mitomycin C was administered initially and mitoxantrone was administered following the same schedule if disease recurred during followup." | 1.29 | Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer. ( Carmignani, G; Maffezzini, M; Raber, M; Simonato, A; Zanon, M, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (16.22) | 18.2507 |
| 2000's | 21 (56.76) | 29.6817 |
| 2010's | 8 (21.62) | 24.3611 |
| 2020's | 2 (5.41) | 2.80 |
| Authors | Studies |
|---|---|
| Bishton, MJ | 1 |
| Rule, S | 1 |
| Wilson, W | 1 |
| Turner, D | 1 |
| Patmore, R | 1 |
| Clifton-Hadley, L | 1 |
| McMillan, A | 1 |
| Lush, R | 1 |
| Haynes, A | 1 |
| Myint, HH | 1 |
| Tandon, S | 1 |
| Narula, G | 1 |
| Prasad, M | 1 |
| Subramanian, P | 1 |
| Patkar, N | 1 |
| Tembhare, P | 1 |
| Gujral, S | 1 |
| Banavali, S | 1 |
| Alexander, TB | 1 |
| Wang, L | 1 |
| Inaba, H | 1 |
| Triplett, BM | 1 |
| Pounds, S | 1 |
| Ribeiro, RC | 1 |
| Pui, CH | 1 |
| Rubnitz, JE | 1 |
| Yoon, S | 1 |
| Kim, H | 1 |
| Hur, M | 1 |
| Han, SH | 1 |
| Chung, HJ | 1 |
| Moon, HW | 1 |
| Yun, YM | 1 |
| Lee, MH | 1 |
| Guolo, F | 1 |
| Minetto, P | 1 |
| Clavio, M | 1 |
| Miglino, M | 1 |
| Colombo, N | 1 |
| Cagnetta, A | 1 |
| Cea, M | 1 |
| Marcolin, R | 1 |
| Todiere, A | 1 |
| Ballerini, F | 1 |
| Gobbi, M | 1 |
| Lemoli, RM | 1 |
| Shi, Y | 1 |
| Su, Z | 1 |
| Li, S | 1 |
| Chen, Y | 1 |
| Chen, X | 1 |
| Xiao, Y | 1 |
| Sun, M | 1 |
| Ping, Q | 1 |
| Zong, L | 1 |
| Ferrero, D | 1 |
| Crisà, E | 1 |
| Marmont, F | 1 |
| Audisio, E | 1 |
| Frairia, C | 1 |
| Giai, V | 1 |
| Gatti, T | 1 |
| Festuccia, M | 1 |
| Bruno, B | 1 |
| Riera, L | 1 |
| Passera, R | 1 |
| Boccadoro, M | 2 |
| Selmeczi, A | 1 |
| Udvardy, M | 1 |
| Illés, A | 1 |
| Telek, B | 1 |
| Kiss, A | 1 |
| Batár, P | 1 |
| Reményi, G | 1 |
| Szász, R | 1 |
| Ujj, Z | 1 |
| Márton, A | 1 |
| Ujfalusi, A | 1 |
| Hevessy, Z | 1 |
| Pinczés, L | 1 |
| Bedekovics, J | 1 |
| Rejtő, L | 1 |
| Munir, T | 1 |
| Howard, DR | 1 |
| McParland, L | 1 |
| Pocock, C | 2 |
| Rawstron, AC | 2 |
| Hockaday, A | 1 |
| Varghese, A | 1 |
| Hamblin, M | 1 |
| Bloor, A | 1 |
| Pettitt, A | 2 |
| Fegan, C | 2 |
| Blundell, J | 1 |
| Gribben, JG | 1 |
| Phillips, D | 1 |
| Hillmen, P | 2 |
| Cohen, DR | 1 |
| Cocks, K | 1 |
| Sayala, HA | 1 |
| Kennedy, DB | 1 |
| Milligan, DW | 1 |
| Radford, J | 1 |
| Mercieca, J | 1 |
| Dearden, C | 1 |
| Ezekwisili, R | 1 |
| Smith, AF | 1 |
| Brown, J | 1 |
| Booth, GA | 1 |
| Varghese, AM | 1 |
| Dombret, H | 2 |
| Gabert, J | 1 |
| Boiron, JM | 1 |
| Rigal-Huguet, F | 1 |
| Blaise, D | 1 |
| Thomas, X | 2 |
| Delannoy, A | 1 |
| Buzyn, A | 2 |
| Bilhou-Nabera, C | 1 |
| Cayuela, JM | 2 |
| Fenaux, P | 1 |
| Bourhis, JH | 1 |
| Fegueux, N | 1 |
| Charrin, C | 1 |
| Boucheix, C | 1 |
| Lhéritier, V | 2 |
| Espérou, H | 1 |
| MacIntyre, E | 2 |
| Vernant, JP | 2 |
| Fière, D | 1 |
| Hawes, D | 1 |
| Liu, PY | 2 |
| Muggia, FM | 2 |
| Wilczynski, S | 1 |
| Cote, R | 1 |
| Felix, J | 1 |
| Terada, K | 1 |
| Belt, RJ | 1 |
| Alberts, DS | 2 |
| Wernstedt, P | 1 |
| Brune, M | 1 |
| Andersson, PO | 1 |
| Gustavsson, B | 1 |
| Stockelberg, D | 1 |
| Wadenvik, H | 1 |
| Ravindranath, Y | 1 |
| Gianni, AM | 2 |
| Magni, M | 2 |
| Martelli, M | 1 |
| Di Nicola, M | 1 |
| Carlo-Stella, C | 1 |
| Pilotti, S | 1 |
| Rambaldi, A | 1 |
| Cortelazzo, S | 1 |
| Patti, C | 2 |
| Parvis, G | 1 |
| Benedetti, F | 1 |
| Capria, S | 2 |
| Corradini, P | 1 |
| Tarella, C | 2 |
| Barbui, T | 1 |
| Venditti, A | 2 |
| Maurillo, L | 2 |
| Buccisano, F | 2 |
| Del Poeta, G | 2 |
| Mazzone, C | 2 |
| Tamburini, A | 2 |
| Del Principe, MI | 2 |
| Consalvo, MI | 2 |
| De Fabritiis, P | 2 |
| Cudillo, L | 1 |
| Picardi, A | 1 |
| Franchi, A | 1 |
| Lo-Coco, F | 1 |
| Amadori, S | 2 |
| Coco, FL | 1 |
| Kern, W | 2 |
| Voskova, D | 1 |
| Schoch, C | 2 |
| Schnittger, S | 1 |
| Hiddemann, W | 2 |
| Haferlach, T | 2 |
| Santini, G | 1 |
| Chisesi, T | 1 |
| Nati, S | 1 |
| Porcellini, A | 1 |
| Zoli, V | 1 |
| Rizzoli, V | 1 |
| Zupo, S | 1 |
| Marino, G | 1 |
| Rubagotti, A | 1 |
| Polacco, A | 1 |
| Spriano, M | 1 |
| Vimercati, R | 1 |
| Congiu, AM | 1 |
| Ravetti, JL | 1 |
| Aversa, S | 1 |
| Candela, M | 1 |
| Wilda, M | 1 |
| Perez, AV | 1 |
| Bruch, J | 1 |
| Woessmann, W | 1 |
| Metzler, M | 1 |
| Fuchs, U | 1 |
| Borkhardt, A | 1 |
| Scholl, C | 1 |
| Schlenk, RF | 1 |
| Eiwen, K | 1 |
| Döhner, H | 1 |
| Fröhling, S | 1 |
| Döhner, K | 1 |
| Robak, T | 1 |
| Blonski, JZ | 1 |
| Gora-Tybor, J | 1 |
| Jamroziak, K | 1 |
| Dwilewicz-Trojaczek, J | 1 |
| Tomaszewska, A | 1 |
| Konopka, L | 1 |
| Ceglarek, B | 1 |
| Dmoszynska, A | 1 |
| Kowal, M | 1 |
| Kloczko, J | 1 |
| Stella-Holowiecka, B | 1 |
| Sulek, K | 1 |
| Calbecka, M | 1 |
| Zawilska, K | 1 |
| Kuliczkowski, K | 1 |
| Skotnicki, AB | 1 |
| Warzocha, K | 1 |
| Kasznicki, M | 1 |
| Lee, S | 1 |
| Kim, YJ | 1 |
| Eom, KS | 1 |
| Min, CK | 1 |
| Kim, HJ | 1 |
| Cho, SG | 1 |
| Lee, JW | 1 |
| Min, WS | 1 |
| Kim, CC | 1 |
| de Labarthe, A | 1 |
| Rousselot, P | 1 |
| Huguet-Rigal, F | 1 |
| Delabesse, E | 1 |
| Witz, F | 1 |
| Maury, S | 1 |
| Réa, D | 1 |
| Vekemans, MC | 1 |
| Reman, O | 1 |
| Pigneux, A | 1 |
| Escoffre, M | 1 |
| Chalandon, Y | 1 |
| Ifrah, N | 1 |
| Ladetto, M | 1 |
| Pagliano, G | 1 |
| De Marco, F | 1 |
| Drandi, D | 1 |
| Ricca, I | 1 |
| Astolfi, M | 1 |
| Matteucci, P | 1 |
| Guidetti, A | 1 |
| Mantoan, B | 1 |
| Bodoni, CL | 1 |
| Zanni, M | 1 |
| Esteve, J | 1 |
| Escoda, L | 2 |
| Martín, G | 1 |
| Rubio, V | 1 |
| Díaz-Mediavilla, J | 1 |
| González, M | 2 |
| Rivas, C | 1 |
| Alvarez, C | 1 |
| González San Miguel, JD | 1 |
| Brunet, S | 1 |
| Tomás, JF | 1 |
| Tormo, M | 1 |
| Sayas, MJ | 2 |
| Sánchez Godoy, P | 1 |
| Colomer, D | 1 |
| Bolufer, P | 1 |
| Sanz, MA | 1 |
| Spagnoli, A | 1 |
| Panetta, P | 1 |
| Neri, B | 1 |
| Ottaviani, L | 1 |
| Fraboni, D | 1 |
| Sarlo, C | 1 |
| Bosch, F | 1 |
| Ferrer, A | 1 |
| Villamor, N | 1 |
| Briones, J | 1 |
| González-Barca, E | 1 |
| Abella, E | 1 |
| Gardella, S | 1 |
| Pérez-Ceballos, E | 1 |
| Asensi, A | 1 |
| Font, L | 1 |
| Altés, A | 1 |
| Muntañola, A | 1 |
| Bertazzoni, P | 1 |
| Rozman, M | 1 |
| Aymerich, M | 1 |
| Giné, E | 1 |
| Montserrat, E | 1 |
| Hirt, C | 1 |
| Schüler, F | 1 |
| Kiefer, T | 1 |
| Schwenke, C | 1 |
| Haas, A | 1 |
| Niederwieser, D | 1 |
| Neser, S | 1 |
| Assmann, M | 1 |
| Srock, S | 1 |
| Rohrberg, R | 1 |
| Dachselt, K | 1 |
| Leithäuser, M | 1 |
| Rabkin, CS | 1 |
| Herold, M | 1 |
| Dölken, G | 1 |
| Narimatsu, H | 1 |
| Yamamoto, F | 1 |
| Kurahashi, S | 1 |
| Sugimoto, T | 1 |
| Sugiura, I | 1 |
| Maffezzini, M | 1 |
| Simonato, A | 1 |
| Zanon, M | 1 |
| Raber, M | 1 |
| Carmignani, G | 1 |
| Wallace, DL | 1 |
| O'Toole, RV | 1 |
| Terada, KY | 1 |
| Franklin, EW | 1 |
| Herrer, GW | 1 |
| Goldberg, DA | 1 |
| Hannigan, EV | 1 |
| Toyosawa, M | 1 |
| Shinohara, K | 1 |
| Ariyoshi, K | 1 |
| Ando, T | 1 |
| Kobayashi, M | 1 |
| Hikiji, K | 1 |
| Topuz, E | 1 |
| Aydiner, A | 1 |
| Saip, P | 1 |
| Bengisu, E | 1 |
| Berkman, S | 1 |
| Disci, R | 1 |
| Meloni, G | 1 |
| Diverio, D | 1 |
| Vignetti, M | 1 |
| Avvisati, G | 1 |
| Petti, MC | 1 |
| Mandelli, F | 1 |
| Lo Coco, F | 1 |
| Moos, M | 1 |
| Schulz, R | 1 |
| Martin, S | 1 |
| Benner, A | 1 |
| Haas, R | 1 |
| Braess, J | 1 |
| Unterhalt, M | 1 |
| Wörmann, B | 1 |
| Büchner, T | 1 |
| Sarris, AH | 1 |
| Jiang, Y | 1 |
| Tsimberidou, AM | 1 |
| Thomaides, A | 1 |
| Rassidakis, GZ | 1 |
| Ford, RJ | 1 |
| Medeiros, LJ | 1 |
| Cabanillas, F | 1 |
| McLaughlin, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase II Trial of Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) With or Without Rituximab in Previously Treated Chronic Lymphocytic Leukemia[NCT00337246] | Phase 2 | 56 participants (Anticipated) | Interventional | 2005-07-31 | Completed | ||
| A RANDOMIZED PHASE III TRIAL COMPARING DEXAMETHASONE WITH PREDNISONE IN INDUCTION TREATMENT AND BONE MARROW TRANSPLANTATION WITH INTENSIVE MAINTENANCE TREATMENT IN ADOLESCENT AND ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL-4)[NCT00002700] | Phase 3 | 392 participants (Anticipated) | Interventional | 1995-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for mitoxantrone and Minimal Disease, Residual
| Article | Year |
|---|---|
Recent advances in pediatric acute lymphoblastic and myeloid leukemia.
Topics: Acute Disease; Antineoplastic Agents; Biomarkers, Tumor; Child; Chromosome Aberrations; Clinical Tri | 2003 |
16 trials available for mitoxantrone and Minimal Disease, Residual
20 other studies available for mitoxantrone and Minimal Disease, Residual
| Article | Year |
|---|---|
Clinicoepidemiologic Profile and Outcome Predicted by Minimal Residual Disease in Children With Mixed-phenotype Acute Leukemia Treated on a Modified MCP-841 Protocol at a Tertiary Cancer Institute in India.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; | 2020 |
Do we still need morphologic evaluation in new era of advanced minimal residual disease analyses?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Hum | 2019 |
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; | 2019 |
Multistep targeted nano drug delivery system aiming at leukemic stem cells and minimal residual disease.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Cell Line, Tumor; Drug Delivery Systems; Durapatite; Fo | 2013 |
[Treatment of acute myeloid leukemia -- a single center experience (2007-2013)].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic | 2014 |
Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Stu | 2002 |
Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
Topics: Adult; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; | 2002 |
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2003 |
Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabi | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone for untreated follicular lymphoma: a report from the non-Hodgkin's lymphoma co-operative study group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Disease- | 2004 |
Use of MLL/GRAF fusion mRNA for measurement of minimal residual disease during chemotherapy in an infant with acute monoblastic leukemia (AML-M5).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; DNA-Binding Proteins; Etoposide; GTPase- | 2005 |
The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromoso | 2005 |
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2006 |
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; | 2007 |
Difficulty of peripheral blood stem cell collection after multiple consolidation therapy in acute myeloid leukemia.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Gr | 2008 |
Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer.
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Trans | 1996 |
[The detection of minimal residual disease by DEK/CAN chimeric m-RNA in a case of AML M2 with translocation t(6;9) (p23;q34) after chemotherapy and peripheral blood stem cell transplantation].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 6; Chromosomes, | 1997 |
Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biom | 1997 |
The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 14; Chromosomes, Hum | 1998 |
Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2000 |